Sam Brusco, Associate Editor02.18.22
Yesterday Baxter reported financial performance for the fourth quarter and full year 2021 (ended December 31). These results reflect 19 days of contribution from Hillrom, which the company acquired on Dec 13.
Fourth quarter sales totaled $3.5 billion, a 10 percent increase over Q4 2020. U.S. sales were $1.5 billion, and international sales reached $2 billion. BioPharma Solutions led the charge by growing over 30 percent over the year prior.
Worldwide 2021 sales were $12.8 billion, growing 10 percent over the previous year. U.S. sales grew 6 percent to $5.2 billion, and international proceeds rose 12 percent to $7.6 billion.
“We remain focused on strategically redeploying capital to advance our performance and position Baxter for future success,” Jay Saccaro, Baxter executive VP and CFO told the press. “This strategy was clearly evidenced during 2021, as the company returned approximately $1.1 billion to shareholders through dividends and share repurchases, and deployed over $12 billion to inorganic investments to fuel growth, including our acquisition of Hillrom.”
Business highlights for 2021 include:
“In 2021, Baxter’s dedicated employees remained focused on responding to the COVID-19 public health crisis while also embracing new opportunities to advance innovation and accelerate performance, all in support of our Mission to Save and Sustain Lives,” said José (Joe) E. Almeida, Baxter chairman, president, and CEO. “Amid a historic pandemic and global supply chain challenges, Baxter achieved solid top- and bottom-line growth for the fourth quarter and full year. Performance reflects sustained demand for our portfolio of medically essential products coupled with the impact of our ongoing transformation. Our December 2021 acquisition of Hillrom creates new potential for our team to advance connected care solutions, expand portfolio access and capture efficiencies to drive enhanced value for patients, clinicians, employees, investors and other stakeholders.”
Fourth quarter sales totaled $3.5 billion, a 10 percent increase over Q4 2020. U.S. sales were $1.5 billion, and international sales reached $2 billion. BioPharma Solutions led the charge by growing over 30 percent over the year prior.
Worldwide 2021 sales were $12.8 billion, growing 10 percent over the previous year. U.S. sales grew 6 percent to $5.2 billion, and international proceeds rose 12 percent to $7.6 billion.
“We remain focused on strategically redeploying capital to advance our performance and position Baxter for future success,” Jay Saccaro, Baxter executive VP and CFO told the press. “This strategy was clearly evidenced during 2021, as the company returned approximately $1.1 billion to shareholders through dividends and share repurchases, and deployed over $12 billion to inorganic investments to fuel growth, including our acquisition of Hillrom.”
Business highlights for 2021 include:
- Closing the $10.5 billion deal for Hillrom in December
- An EU nod for the NEPHROCLEAR CCL1 Acute Kidney Injury (AKI) test with partner bioMérieux
- Launch of PrisMax 2 for continuous renal replacement therapy (CRRT) and other organ support therapies
- Release of Sharesource Analytics 1.0 for home-based peritoneal dialysis
“In 2021, Baxter’s dedicated employees remained focused on responding to the COVID-19 public health crisis while also embracing new opportunities to advance innovation and accelerate performance, all in support of our Mission to Save and Sustain Lives,” said José (Joe) E. Almeida, Baxter chairman, president, and CEO. “Amid a historic pandemic and global supply chain challenges, Baxter achieved solid top- and bottom-line growth for the fourth quarter and full year. Performance reflects sustained demand for our portfolio of medically essential products coupled with the impact of our ongoing transformation. Our December 2021 acquisition of Hillrom creates new potential for our team to advance connected care solutions, expand portfolio access and capture efficiencies to drive enhanced value for patients, clinicians, employees, investors and other stakeholders.”